DE60312513T2 - Zusammensetzungen und verfahren zum nachweis vom apo-b48 und apo-b100 - Google Patents

Zusammensetzungen und verfahren zum nachweis vom apo-b48 und apo-b100 Download PDF

Info

Publication number
DE60312513T2
DE60312513T2 DE60312513T DE60312513T DE60312513T2 DE 60312513 T2 DE60312513 T2 DE 60312513T2 DE 60312513 T DE60312513 T DE 60312513T DE 60312513 T DE60312513 T DE 60312513T DE 60312513 T2 DE60312513 T2 DE 60312513T2
Authority
DE
Germany
Prior art keywords
apo
antibody
sample
antibodies
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60312513T
Other languages
German (de)
English (en)
Other versions
DE60312513D1 (de
Inventor
Jamila Najib
Zouher Majd
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genfit SA
Original Assignee
Genfit SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genfit SA filed Critical Genfit SA
Publication of DE60312513D1 publication Critical patent/DE60312513D1/de
Application granted granted Critical
Publication of DE60312513T2 publication Critical patent/DE60312513T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Light Receiving Elements (AREA)
DE60312513T 2002-06-19 2003-06-19 Zusammensetzungen und verfahren zum nachweis vom apo-b48 und apo-b100 Expired - Fee Related DE60312513T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0207542A FR2841249A1 (fr) 2002-06-19 2002-06-19 Compositions et methodes pour le dosage de l'apo b48 et de l'apo b100
FR0207542 2002-06-19
PCT/FR2003/001888 WO2004000884A2 (fr) 2002-06-19 2003-06-19 Compositions et methodes pour le dosage de l'apo b48 et de l'apo b100

Publications (2)

Publication Number Publication Date
DE60312513D1 DE60312513D1 (de) 2007-04-26
DE60312513T2 true DE60312513T2 (de) 2007-12-06

Family

ID=29719858

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60312513T Expired - Fee Related DE60312513T2 (de) 2002-06-19 2003-06-19 Zusammensetzungen und verfahren zum nachweis vom apo-b48 und apo-b100

Country Status (11)

Country Link
US (1) US20050152900A1 (enExample)
EP (1) EP1513878B1 (enExample)
JP (1) JP2006515561A (enExample)
AT (1) ATE356832T1 (enExample)
AU (1) AU2003267493A1 (enExample)
CA (1) CA2489057A1 (enExample)
DE (1) DE60312513T2 (enExample)
DK (1) DK1513878T3 (enExample)
ES (1) ES2283803T3 (enExample)
FR (1) FR2841249A1 (enExample)
WO (1) WO2004000884A2 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2005093415A1 (ja) * 2004-03-29 2008-02-14 株式会社シバヤギ アポリポタンパク質ｂ−４８の測定方法およびその用途
WO2007058588A1 (en) * 2005-11-18 2007-05-24 T.A.C Thrombosis And Coagulation Aktiebolag Monoclonal antibodies against apolipoprotein m
JP2009531712A (ja) * 2006-03-23 2009-09-03 デ グスマン ブレイヤー、エメリタ アポリポタンパク質フィンガープリント技術
US8088593B2 (en) 2007-10-02 2012-01-03 Theranos, Inc. Modular point-of-care devices, systems, and uses thereof
JP5832723B2 (ja) * 2009-03-06 2015-12-16 協和メデックス株式会社 可溶性インターロイキン−２受容体定量用標準品
EP2408812B1 (en) * 2009-03-17 2015-12-16 CardioVax, LLC Immunomodulatory methods and systems for treatment and/or prevention of atherosclerosis and related proteins, peptides and compositions
WO2011060329A1 (en) 2009-11-14 2011-05-19 Kuang-Yuh Chyu Immunomodulatory methods and systems for treatment and/or prevention of atherosclerosis
US8506964B2 (en) 2010-02-05 2013-08-13 Cardiovax, Llc Fusion proteins and related compositions, methods and systems for treatment and/or prevention of atherosclerosis
RU2013126628A (ru) 2010-11-12 2014-12-20 Седарс-Синаи Медикал Сентер Иммуномодулирующие способы и системы для лечения и/или предотвращения аневризм
CA2817543A1 (en) 2010-11-12 2012-06-07 Cedars-Sinai Medical Center Immunomodulatory methods and systems for treatment and/or prevention of hypertension
CN106323875B (zh) 2011-01-21 2019-07-09 西拉诺斯知识产权有限责任公司 样品使用最大化的系统和方法
US20140170735A1 (en) 2011-09-25 2014-06-19 Elizabeth A. Holmes Systems and methods for multi-analysis
US8475739B2 (en) 2011-09-25 2013-07-02 Theranos, Inc. Systems and methods for fluid handling
US9268915B2 (en) 2011-09-25 2016-02-23 Theranos, Inc. Systems and methods for diagnosis or treatment
US9664702B2 (en) 2011-09-25 2017-05-30 Theranos, Inc. Fluid handling apparatus and configurations
US9632102B2 (en) 2011-09-25 2017-04-25 Theranos, Inc. Systems and methods for multi-purpose analysis
US10012664B2 (en) 2011-09-25 2018-07-03 Theranos Ip Company, Llc Systems and methods for fluid and component handling
US9810704B2 (en) 2013-02-18 2017-11-07 Theranos, Inc. Systems and methods for multi-analysis
US9250229B2 (en) 2011-09-25 2016-02-02 Theranos, Inc. Systems and methods for multi-analysis
US11008628B1 (en) 2013-02-18 2021-05-18 Labrador Diagnostics Llc Systems and methods for analyte testing and laboratory oversight
US10401373B1 (en) 2013-02-18 2019-09-03 Theranos Ip Company, Llc Systems and methods for analyte testing and laboratory oversight
US10422806B1 (en) 2013-07-25 2019-09-24 Theranos Ip Company, Llc Methods for improving assays of biological samples
US11360107B1 (en) 2014-02-25 2022-06-14 Labrador Diagnostics Llc Systems and methods for sample handling
CN106053793A (zh) * 2016-06-20 2016-10-26 诺莱生物医学研究院（北京）有限公司 一种快速检测乳糜血的免疫层析试纸卡及其制备方法
WO2025111449A1 (en) * 2023-11-21 2025-05-30 Sun Diagnostics, Inc. Method and reagent to clear turbidity due to elevated triglycerides in a biological specimen

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60193926A (ja) * 1984-03-15 1985-10-02 Tokyo Daigaku 単クローン性抗ヒトアポリポ蛋白質ｂ１００抗体
JPS617299A (ja) * 1984-06-20 1986-01-13 Dai Ichi Pure Chem Co Ltd ヒトアポリポ蛋白ｂ４８に高い特異性を有する単クローン性抗体
US6635623B1 (en) * 1997-06-13 2003-10-21 Baylor College Of Medicine Lipoproteins as nucleic acid vectors

Also Published As

Publication number Publication date
WO2004000884A2 (fr) 2003-12-31
DE60312513D1 (de) 2007-04-26
FR2841249A1 (fr) 2003-12-26
ES2283803T3 (es) 2007-11-01
ATE356832T1 (de) 2007-04-15
DK1513878T3 (da) 2007-07-16
AU2003267493A1 (en) 2004-01-06
US20050152900A1 (en) 2005-07-14
CA2489057A1 (fr) 2003-12-31
EP1513878A2 (fr) 2005-03-16
EP1513878B1 (fr) 2007-03-14
JP2006515561A (ja) 2006-06-01
WO2004000884A3 (fr) 2004-04-08

Similar Documents

Publication Publication Date Title
ES2283803T3 (es) Composiciones y procedimientos para la dosificacion de la apo b48 y de la apo b100.
US8673593B2 (en) Antibodies to alpha-synuclein
CA2498058C (en) N-11 truncated amyloid-beta monoclonal antibodies, compositions, methods and uses
WO2007021255A1 (en) Antibodies to alpha-synuclein
DE69119656T2 (de) Satz zur spezifischen Bestimmung von Angiotensin-II
KR101883515B1 (ko) 알츠하이머 병의 진단약 및 진단 방법
CA2274776C (en) Method for analyzing annexin v in urine and use thereof
JP3259768B2 (ja) 腎疾患の検査方法
DE69112225T2 (de) Immunodiagnostische probe für gelenkrheumatismus.
DE69733957T2 (de) Verfahren zur bestimmung der gegenwart des gehirnspezifischen proteins s-100 beta
DE69224134T2 (de) Monoklonale Antikörper gegen Hepatitis-C-Virus
Saito et al. Marked increases in concentrations of apolipoprotein in the cerebrospinal fluid of poliovirus-infected macaques: relations between apolipoprotein concentrations and severity of brain injury
JP3018110B2 (ja) モノクローナル抗体
DE69921987T2 (de) IMMUNTEST FÜR HUMAN CHROMOGRANINE A (CgA), ANTIKÖRPER, REAGENZ UND DAZU GEEIGNETER TESTSATZ
DE60037115T2 (de) Diagnostischer test für menschlisches matrix gla-protein und seine verwendung als biomarker
DE68911713T2 (de) Monoklonale Antikörper, die atriales natriuretisches Polypeptide erkennen, ihre Herstellung und Verwendung.
DE3924924A1 (de) Verfahren zum nachweis und/oder der quantitativen bestimmung von komplementpeptid c5a und/oder c5adesarg
DE68914345T2 (de) Gamma-atriales, natriuretisches Polypeptid erkennende monoklonale Antikörper, solche Antikörper produzierende Hybridome und deren Herstellung und Verwendung.
EP0696597A2 (de) Monoklonale Antikörper zur selektiven immunologischen Bestimmung von hochmolekularen, intakten Lamininformen in Körperflüssigkeiten
RU2439160C1 (ru) Способ получения моноклональных антител к аблюминальному мембранному антигену церебральных эндотелиоцитов
DE60127081T2 (de) Gegen den aktiven, jedoch nicht den inaktiven Hepatozytenwachstumsfaktoraktivator (HGFA) gerichteter spezifischer Antikörper
DE2811003A1 (de) Immunverfahren zur bestimmung von beta-endorphin sowie antigen und antikoerper hierfuer
DE60216482T2 (de) Zusammensetzungen und verfahren zum bestimmen von aa4rp
EP1430304B1 (de) Verfahren zur diagnose von chronisch entzündlichen darmerkrankungen
US20040137521A1 (en) Method for apo clll measurement in apo b and non apo b containing particles

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee